The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents
- PMID: 29522099
- DOI: 10.1093/ibd/izx115
The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents
Abstract
Aim: There is a paucity of data on the clinical course and the factors affecting the clinical course of herpes zoster (HZ) in inflammatory bowel disease (IBD). Our aim was to determine the impact of anti-TNF therapy and other factors on the clinical course of HZ in IBD patients.
Methods: We conducted a retrospective cohort study among a cohort of nation-wide Veterans Affairs patients with IBD who developed incident HZ. The exposed group consisted of eligible study patients who were actively exposed to anti-TNF alone or anti-TNF plus thiopurines at the time of HZ onset. The unexposed group consisted of patients who were only exposed to 5-ASA agents before the onset of HZ without any exposure to anti-TNF medications. The outcome of interest was the development of severe HZ that was defined by including various HZ complications.
Results: A total of 295 patients were identified with an incident HZ flare during follow- up duration, and among them 69 met the definition of having a severe flare. In multivariable logistic regression analysis adjusting for sex, age at HZ flare onset, race, Charlson comorbidity score, and receipt of oral anti-HZ treatment, exposure to anti-TNF agent was not associated with an increased risk of severe HZ flare compared to exposure to mesalamine alone (adjusted relative risk (RR) 1.1, 95% confidence intervals (CI): 0.75-1.55). Among the covariates, receipt of oral anti-HZ treatment (adjusted RR 0.42, 95% CI: 0.29-0.61), advancing age at HZ onset (adjusted RR for each year increase in age 1.02, 95% CI: 1.00-1.04), and African-American race (adjusted RR with whites as reference 1.58, 95% CI: 1.02-2.44) were significantly associated with the risk of having severe HZ flare.
Conclusion: Our study showed that among IBD patients who developed HZ, treatment with anti-TNF agents was not associated with increased risk of developing severe HZ as compared to patients treated with 5-ASA therapy only. 10.1093/ibd/izx115_video1izx115_Video_15786486963001.
Comment in
-
Improving Vaccination Rates for IBD Patients Through the Use of Local Pharmacies.Inflamm Bowel Dis. 2019 Feb 21;25(3):e19. doi: 10.1093/ibd/izy209. Inflamm Bowel Dis. 2019. PMID: 29893866 No abstract available.
-
Factors Predicting Severity of Herpes and Improving Herpes Vaccination Among IBD Patients.Inflamm Bowel Dis. 2019 Feb 21;25(3):e24. doi: 10.1093/ibd/izy218. Inflamm Bowel Dis. 2019. PMID: 29893923 No abstract available.
Similar articles
-
Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies.Eur J Clin Microbiol Infect Dis. 2020 Feb;39(2):219-227. doi: 10.1007/s10096-019-03706-9. Epub 2019 Oct 18. Eur J Clin Microbiol Infect Dis. 2020. PMID: 31650411 Review.
-
Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.Clin Gastroenterol Hepatol. 2018 Dec;16(12):1919-1927.e3. doi: 10.1016/j.cgh.2017.12.052. Epub 2018 Jan 5. Clin Gastroenterol Hepatol. 2018. PMID: 29309905
-
Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications.Aliment Pharmacol Ther. 2017 Oct;46(7):668-672. doi: 10.1111/apt.14257. Epub 2017 Aug 14. Aliment Pharmacol Ther. 2017. PMID: 28805309
-
Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.Aliment Pharmacol Ther. 2013 Feb;37(4):420-9. doi: 10.1111/apt.12182. Epub 2012 Dec 13. Aliment Pharmacol Ther. 2013. PMID: 23240738 Free PMC article.
-
Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary.Inflamm Bowel Dis. 2016 Oct;22(10):2538-47. doi: 10.1097/MIB.0000000000000902. Inflamm Bowel Dis. 2016. PMID: 27598743 Review.
Cited by
-
Incidence and risk of herpes zoster in patients with ulcerative colitis and Crohn's disease in the USA.Gastroenterol Rep (Oxf). 2023 Apr 12;11:goad016. doi: 10.1093/gastro/goad016. eCollection 2023. Gastroenterol Rep (Oxf). 2023. PMID: 37064550 Free PMC article.
-
Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies.Eur J Clin Microbiol Infect Dis. 2020 Feb;39(2):219-227. doi: 10.1007/s10096-019-03706-9. Epub 2019 Oct 18. Eur J Clin Microbiol Infect Dis. 2020. PMID: 31650411 Review.
-
Herpes zoster infection in patients with inflammatory bowel disease.Korean J Intern Med. 2025 May;40(3):347-356. doi: 10.3904/kjim.2024.342. Epub 2025 Apr 30. Korean J Intern Med. 2025. PMID: 40360218 Free PMC article. Review.
-
Increased Risk of Herpes Zoster in Young and Metabolically Healthy Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.Gut Liver. 2019 May 15;13(3):333-341. doi: 10.5009/gnl18304. Gut Liver. 2019. PMID: 30602222 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous